Biglycan is internalized via a chlorpromazine-sensitive route.
The small leucine-rich proteoglycan biglycan (BGN) is abundantly expressed in mesenchymal tissues. Its expression level is related to the phenotypic differentiation of cells. A dysregulation in BGN expression occurs under several pathological conditions, including glomerulonephritis, mesothelioma, pancreatic cancer and a mouse model of osteoporosis. Since the extracellular concentration of BGN is regulated both by secretion and endocytosis, we performed mechanistic studies on BGN endocytosis in human skin fibroblasts in vitro, using inhibitors of different endocytic routes. Chlorpromazine, an inhibitor of the clathrin-coated pit-pathway reduced endocytosis of BGN in human skin fibroblasts by 40%, and decreased degradation of BGN by 66% Filipin, an inhibitor of the caveolae pathway, and Tyrphostin AG 1478, a specific inhibitor of EGF-receptor phosphorylation that partially inhibits endocytosis of the structurally related proteoglycan decorin, had no influence on BGN internalization and degradation. Our data indicates that the classical clathrin-mediated endocytic pathway is a major route for the internalization of BGN. Based on the differential susceptibility to pharmacological inhibition, it appears that BGN endocytosis seems to be at least in part mechanistically different from decorin uptake.
Götte
Martin
M
Department of Physiological Chemistry, Münster University Hospital, Domagkstr. 11, D-48149 Münster, Germany. mgotte@uni-muenster.de
Sofeu Feugaing
David Denis
DD
Kresse
Hans
H
D058578:Biglycan; D021941:Caveolae / Q000378:metabolism; D002478:Cells, Cultured; D002746:Chlorpromazine / Q000494:pharmacology*; D022163:Clathrin-Coated Vesicles / Q000378:metabolism; D058575:Decorin; D004705:Endocytosis / Q000187:drug effects* / Q000502:physiology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D066246:ErbB Receptors / Q000378:metabolism; D016326:Extracellular Matrix Proteins; D005347:Fibroblasts / Q000378:metabolism*; D005372:Filipin / Q000494:pharmacology*; D006801:Humans; D010766:Phosphorylation; D011509:Proteoglycans / Q000378:metabolism*; D011799:Quinazolines; D012867:Skin / Q000166:cytology; D020032:Tyrphostins / Q000494:pharmacology
C546884:BGN protein, human; C546885:Bgn protein, mouse; D058578:Biglycan; C546878:DCN protein, human; C546879:Dcn protein, mouse; D058575:Decorin; D004791:Enzyme Inhibitors; D016326:Extracellular Matrix Proteins; D011509:Proteoglycans; D011799:Quinazolines; D020032:Tyrphostins; C101044:RTKI cpd; D005372:Filipin; D066246:ErbB Receptors; D002746:Chlorpromazine